Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Traws Pharma, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- 0 vs. Q4 2024
- Shares held
- 1.73M
- +561.9K (+48.0%) vs. Q4 2024
- Total value
- $3.98M
- −$6.26M (−61.1%) vs. Q4 2024
- New holders
- 3
- 8 more added
- Sold out
- 3
- 4 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRAW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $5.19M |
| Q1 2026 | 28 | $6.62M |
| Q4 2025 | 22 | $3.86M |
| Q3 2025 | 18 | $2.41M |
| Q2 2025 | 19 | $1.87M |
| Q1 2025 | 19 | $3.98M |
| Q4 2024 | 19 | $10.2M |
| Q3 2024 | 12 | $3.80M |
| Q2 2024 | 30 | $1.36M |
| Q1 2024 | 26 | $1.88M |
| Q4 2023 | 27 | $1.35M |
| Q3 2023 | 28 | $1.27M |
| Q2 2023 | 24 | $2.19M |
| Q1 2023 | 25 | $1.04M |
| Q4 2022 | 29 | $1.01M |
| Q3 2022 | 30 | $1.54M |
| Q2 2022 | 32 | $2.36M |
| Q1 2022 | 28 | $3.60M |
| Q4 2021 | 34 | $6.14M |
| Q3 2021 | 37 | $10.5M |
| Q2 2021 | 24 | $10.9M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Traws Pharma, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 605,531 | $1.39M | 0.03% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 421,781 | $970.1K | 0.03% | +257,624+156.9% | Added |
| Adage Capital Partners GP, L.L.C. | 330,000 | $759.0K | 0.00% | +330,000 | New |
| Vestal Point Capital, LP | 175,000 | $402.5K | 0.03% | +100,000+133.3% | Added |
| Alyeska Investment Group, L.P. | 52,630 | $121.0K | 0.00% | −64,084−54.9% | Reduced |
| Geode Capital Management, LLC | 33,379 | $76.8K | 0.00% | +12,578+60.5% | Added |
| Boothbay Fund Management, LLC | 33,305 | $76.6K | 0.00% | +4,874+17.1% | Added |
| Ikarian Capital, LLC | 28,493 | $65.5K | 0.02% | −70,000−71.1% | Reduced |
| UBS Group AG | 14,323 | $32.9K | 0.00% | +13,532+1,710.7% | Added |
| Vanguard Group Inc | 13,173 | $30.3K | 0.00% | +32+0.2% | Added |
| Millennium Management LLC | 10,071 | $23.2K | 0.00% | +59+0.6% | Added |
| BlackRock, Inc. | 9,956 | $22.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,261 | $7.50K | 0.00% | +3,261 | New |
| Morgan Stanley | 725 | $1.67K | 0.00% | −15,000−95.4% | Reduced |
| SBI Securities Co., Ltd. | 507 | $1.17K | 0.00% | +352+227.1% | Added |
| Vermillion & White Wealth Management Group, LLC | 96 | $221 | 0.00% | −109−53.2% | Reduced |
| Bank of America Corp | 76 | $175 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 2 | $5 | 0.00% | +2 | New |
| Cornerstone Planning Group LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −10,052−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1,164−100.0% | Sold out |
| Pacific Capital Wealth Advisors, Inc | 0 | $0 | 0.00% | −2−100.0% | Sold out |